(Q36584400)

15 August 2017

1 reference

title

Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines (English)

1 reference

15 August 2017

1 reference

1

Allan Hildesheim

0 references

Silvia Franceschi

object named as

Silvia Franceschi

series ordinal

4

0 references

Lauri E Markowitz

series ordinal

2

object named as

Lauri Markowitz

1 reference

15 August 2017

author name string

Mauricio Hernandez Avila

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

19 June 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

24 Suppl 3

1 reference

15 August 2017

page(s)

S3/227-32

1 reference

American Cancer Society guideline for the early detection of cervical neoplasia and cancer

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.102

Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.102

Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.102

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.102

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.102

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.102

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.102

The promise of global cervical-cancer prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.102

Cost-effectiveness of cervical-cancer screening in five developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.102

Improving adolescent health: focus on HPV vaccine acceptance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.102

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.102

"Proving the null hypothesis" in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.102

A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.102

Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.102

10.1016/J.VACCINE.2006.05.102

7 January 2021

Identifiers

DOI

1 reference

15 August 2017

1 reference